Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection

AIDS

Volumn 28, Issue 5, 2014, Pages 793-795

  Schneider Hohendorf, Tilman ^a   Philipp, Konstanze ^a   Husstedt, Ingo W ^a   Wiendl, Heinz ^a   Schwab, Nicholas ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; L SELECTIN; NATALIZUMAB; ZIDOVUDINE;

ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; CHEMISTRY; COHORT ANALYSIS; COMPLICATION; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PATHOLOGY; PROGNOSIS;

BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; HIV INFECTIONS; HUMANS; L-SELECTIN; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PROGNOSIS;

EID: 84897976866     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000201     Document Type: Article

References (17)

1. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61:35-47.
2. Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin Neurol 1999; 19:193-200.
3. Casado JL, Corral I, García J, Martinez-San Millán J, Navas E, Moreno A, et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis doi:10.1007/s10096-013-1941-6; [Published Online First: 16 August 2013].
4. Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81:93-111.
5. Iannetta M, Bellizzi A, Menzo Lo S, Anzivino E, D'Abramo A, Oliva A, et al. HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus noncoding control region rearrangements and host immunity. J Neurovirol 2013; 19:274-279.
6. Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy: insights into integrin (L(2 in JC virus control. Neurology 2012; 78:458-467.
7. Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner M-P, Jilek S, et al. Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 2012; 18:335-344.
8. Biogen Idec, Medical Information. PML incidence in patients receiving TYSABRI (natalizumab). Available at: http://medinfo.biogenidec.com/. [Accessed September 2013]
9. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81:865-871.
10. Marschner S, Freiberg BA, Kupfer A, Hünig T, Finkel TH. Ligation of the CD4 receptor induces activation-independent down-regulation of L-selectin. Proc Natl Acad Sci U S A 1999; 96:9763-9768.
11. Kourtis AP, Nesheim SR, Thea D, Ibegbu C, Nahmias AJ, Lee FK. Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. AIDS 2000; 14:2429-2436.
12. Wang J, Marschner S, Finkel TH. CXCR4 engagement is required for HIV-1-induced L-selectin shedding. Blood 2004; 103:1218-1221.
13. Jackson LA, Drevets DA, Dong Z-M, Greenfield RA, Murphy JW. Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. J Infect Dis 2005; 191:1361-1367.
14. Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9:625-636.
15. Cinque P, Bossolasco S, Brambilla AM, Boschini A, Mussini C, Pierotti C, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 (Suppl 1):73-80.
16. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
17. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44:341-349.